Skip to content

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$509M+9.9%
Arvinas logo
ArvinasARVN
$700K0.0%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$119K-7.0%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$274K-5.8%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$537K-20.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$723K-12.0%

Other financials

Income statement

See full
Operating income-$17.2M-80.5%
Net income-$32.9M-260%
EPS (diluted)-$1.73+26.1%

Balance sheet

See full
Cash & equivalents$32.8M+24.3%
Total debt$691.0K-38.2%
Total equity$49.3M+32.1%
Total assets$71.6M+64.5%

Cash flow

See full
Operating cash flow-$20.9M-42.5%
CapEx$28.0K-15.2%
Free cash flow-$26.0M+1.1%

Valuation

See full
Market cap$86.33M+223%
Enterprise value$54.18M

Returns & leverage

See full
Return on equity-298.8%-726pp
Debt / equity0.0×
Current ratio10.4×+3.1×

Where this comes from

Reported directly by LONA in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: LONA’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about LONA's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LONA's D&A?
LONA (LONA) reported D&A of $231K in Q1 2026.
How has LONA's D&A changed year-over-year?
LONA's D&A decreased by 4.9% year-over-year, from $243K to $231K.
What is the long-term trend for LONA's D&A?
Over 4 years (2021 to 2025), LONA's D&A has grown at a 16.6% compound annual growth rate (CAGR), from $479K to $886K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.